131 related articles for article (PubMed ID: 6578873)
1. Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.
Coonley CJ; Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1983 Oct; 67(10):949-50. PubMed ID: 6578873
[No Abstract] [Full Text] [Related]
2. Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma.
Stanton G; Casper ES; Friedman B
Cancer Treat Rep; 1985; 69(7-8):915-6. PubMed ID: 3860298
[No Abstract] [Full Text] [Related]
3. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.
Hakes TB; Daghestani AN; Dougherty JB; Weiselberg L; Raymond V
Cancer Treat Rep; 1985 May; 69(5):559-60. PubMed ID: 3859369
[No Abstract] [Full Text] [Related]
4. Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.
Harper HD; Kemeny NE; Ahmed T; Cheng E; Arena F; Sordillo P; Faye L
Cancer Treat Rep; 1984 Apr; 68(4):689-90. PubMed ID: 6585273
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
Lopez M; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N; Lazzaro B
Cancer Treat Rep; 1986 Jul; 70(7):911-2. PubMed ID: 3459575
[No Abstract] [Full Text] [Related]
6. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Joss RA; Obrecht JP; Alberto P; Siegenthaler P; VanHelvoirt A; Cavalli F
Cancer Treat Rep; 1984 Mar; 68(3):563-4. PubMed ID: 6322990
[No Abstract] [Full Text] [Related]
8. Phase II study of idarubicin in advanced endometrial carcinoma.
Hakes TB; Raymond V
Cancer Treat Rep; 1987 May; 71(5):535-6. PubMed ID: 3471330
[No Abstract] [Full Text] [Related]
9. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial of rubidazone in solid tumors and malignant lymphomas.
Skovsgaard T; Hansen HH; Mouridsen HT; Nissen NI; Pedersen-Bjergaard J
Cancer Treat Rep; 1978 Jul; 62(7):1053-8. PubMed ID: 356967
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Kavanagh JJ; Yeung KY; Savaraj N; Krakoff IH
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1187-9. PubMed ID: 3865774
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract.
Einzig A; Kelsen D; Cheng E; Sordillo P; Raymond V; Magill G
Cancer Treat Rep; 1984 Nov; 68(11):1415-6. PubMed ID: 6594197
[No Abstract] [Full Text] [Related]
13. Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Wander HE; Meyer D; Schuff-Werner P; Nagel GA
Onkologie; 1986 Aug; 9(4):236-8. PubMed ID: 3531951
[No Abstract] [Full Text] [Related]
14. Phase II trial of idarubicin in patients with pancreatic cancer.
Mittelman A; Magill GB; Raymond V; Sternberg CN; Cheng EW; Sordillo PB; Young CW
Cancer Treat Rep; 1987 Jun; 71(6):657-8. PubMed ID: 3472656
[No Abstract] [Full Text] [Related]
15. Phase II trial of idarubicin in patients with advanced lymphoma.
Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
[TBL] [Abstract][Full Text] [Related]
16. Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.
Eridani S; Slater NG; Singh AK; Pearson TC
Blut; 1985 Jun; 50(6):369-72. PubMed ID: 3859341
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.
Casper ES; Raymond V; Hakes TB; Currie VE; Kaufman RJ
Cancer Treat Rep; 1987 Dec; 71(12):1289-90. PubMed ID: 3480045
[No Abstract] [Full Text] [Related]
18. [Evaluation of 4-demethoxydaunorubicin toxicity (IMI 30). Preliminary data].
Nobile MT; Pronzato P; Campora E; Ardizzoni A; Grimaldi A; Lionetto R; Repetto L; Rosso R
G Ital Chemioter; 1985; 32(1):29-30. PubMed ID: 3913619
[No Abstract] [Full Text] [Related]
19. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
[TBL] [Abstract][Full Text] [Related]
20. Effect of 4-demethoxydaunorubicin (4-DMDR) in chronic myeloid leukemia in blastic transformation and relapsed acute leukemias.
Bandini G; Comotti B; Scapoli G; Leoni F; Di Prisco U; Mangoni L; Battista R; Tura S
Haematologica; 1985; 70(2):155-9. PubMed ID: 3924779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
